Why MeiraGTx Holdings plc’s (MGTX) Stock Is Up 5.54%
As of Wednesday, August 19, MeiraGTx Holdings plc’s MGTX share price has surged by 5.54%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Commentary & Analysis
Why MeiraGTx Holdings plc’s (MGTX) Stock Is Up 5.63%
As of Thursday, August 13, MeiraGTx Holdings plc’s MGTX share price has surged by 5.63%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About MeiraGTx Holdings plc's Q3 Earnings
MeiraGTx Holdings plc's fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (MGTX) missed or beat analyst's expectations.Jenna Brashear
Is MeiraGTx Holdings plc (MGTX) Overvalued?
We dive into why MeiraGTx Holdings plc (MGTX) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Why MeiraGTx Holdings plc’s (MGTX) Stock Is Up 6.20%
As of Monday, July 27, MeiraGTx Holdings plc’s MGTX share price has surged by 6.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MGTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,069.0 | $255.7 | 47% |
|
| Shares Out (Mil) | 93.8 | 54.2 | 61% |
|
| Institutional Ownership | 92.4% | 93.1% | 61% |
|
| Float (Mil) | 53.7 | 41.4 | 48% |
|
| Beta | 1.27 | 0.95 | 74% |
|
| Avg Daily Volume (000s) | 1,192 | 706 | 71% |
|
| Price Change (52-week) |
36.1% | 50.7% | 78% |
|
| Growth | MGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 39.2% | 13.2% | 93% |
|
| Net Income (5yr) | (14.5%) | (10.1%) | 26% |
|
| EPS (5yr) | 1.6% | 15.8% | 33 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.0% | (15.6%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.473) | $0.510 | ($1.525) | |
| Month Ago EPS | ($0.455) | $0.510 | ($1.390) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.500) | ($1.467) | ($1.392) | |
| Year/Year Chg | (127.7%) | (135.9%) | 11.3% | |
| Financials | MGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $398 | $37 | 38% |
|
| Net Income (TTM) (Mil) | $79 | ($44) | 59% |
|
| EPS (TTM) | $0.943 | ($1.600) | 60% |
|
| Operating Cash Flow (TTM) (Mil) | $14 | ($32) | 39% |
|
| Net Cash Flow (TTM) (Mil) | $111 | $2 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $110 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $1,242 | $174 | 43% |
|
| Valuation | MGTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.86 | 2.50 | 79% |
|
| P/E | 11.9 | 18.6 | 27% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 7.4 | 1.0 | 92% |
|
| Ratios | MGTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 97.9% | 68.8% | 96% |
|
| Net Margin | 19.9% | (72.5%) | 78% |
|
| ROA | 26.5% | (47.6%) | 98% |
|
| ROE | 72.3% | (54.9%) | 95% |
|
| Liabilities to Assets | 45.6% | 29.3% | 37% |
|
| F-Score | 6 | 3 | 67% |
|
MeiraGTx Holdings plc did not pass any screens on 9/29/2026.
